In a NASH model, the administration of this antagonist showed a significant decrease in liver triglycerides (TG) levels, as well as in serum concentrations of aspartate amino transferase (AST) and alanine aminotransferase (ALT); additionally, they observed an improvement in steatosis and fibrosis in histopathological analysis (49). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.